Android Apple

Uptake Of Novel Non-Opioid Drug Suzetrigine Could Benefit From No Pain Act

By Forbes   |   1 month ago
Uptake Of Novel Non-Opioid Drug Suzetrigine Could Benefit From No Pain Act

Vertex's suzetrigine showed positive Phase 3 results, presenting as a promising non-opioid pain treatment. The FDA will decide on its approval in January 2025. The No Pain Act aims to increase non-opioid pain management access, potentially reducing opioid use disorders.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.